• I-many (Edison, New Jersey/Philadelphia), a provider of contract management software and services, introduced its new I-many Contract Management Suite for Life Science at a customer event in Philadelphia. Built on I-many's service-oriented architecture, the company said that the Contract Management Suite for Life Sciences spans the contract management continuum, from the core functions of contract authoring and compliance to sophisticated analytics and business intelligence — all in a single, integrated platform. The core modules of the product include several solutions specifically developed to handle the industry's most pressing issues.

• King Pharmaceuticals (Bristol, Tennessee) reported FDA approval of the company's Thrombin-JMI Epistaxis Kit, a new intranasal spray delivery device. The kit offers healthcare professionals in the emergency department and trauma center a convenient new option to achieve fast, active hemostasis during nose bleeds. Thrombin-JMI is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and has clotting mechanisms.

• MedSolutions (Nashville) reported it will introduce Outcomes-Focuses Cardiac Imaging system at the AHIP 2007 ongoing this week in Las Vegas. The system will manage diagnostic cardiac imaging and reduce costs from unnecessary testing.

• Neoprobe (Dublin, Ohio) reported favorable results from a multi-center Phase II clinical study of its lead clinical candidate, Lymphoseek. Lymphoseek is a radioactive targeting agent being developed for use with handheld gamma detection devices, such as Neoprobe's neo2000system, in a surgical procedure known as Sentinel Lymph Node Biopsy. This study is being conducted at five of the leading cancer centers in the U.S.: John Wayne Cancer Center; M.D. Anderson, the University of California, San Francisco; University Hospitals – Cleveland (Case Western Reserve); and the University of Louisville.

• Synthmed (Iselin, New Jersey) said it has been informed by the FDA that a meeting of the Circulatory System Devices Advisory Panel has been scheduled for Sept. 19, 2007, to review the company's premarket approval application for its Repel-CV Adhesion Barrier product. Repel-CV is a bioresorable film designed to be placed over the surface of the heart at the conclusion of an open heart surgical procedure to reduce the formation of post- operative adhesions.